GluN2A-Selective Pyridopyrimidinone Series of NMDAR Positive Allosteric Modulators with an Improved in Vivo Profile.

The N-methyl-d-aspartate receptor (NMDAR) is an ionotropic glutamate receptor, gated by the endogenous coagonists glutamate and glycine, permeable to Ca2+ and Na+. NMDAR dysfunction is associated with numerous neurological and psychiatric disorders, including schizophrenia, depression, and Alzheimer's disease. Recently, we have disclosed GNE-0723 (1), a GluN2A subunit-selective and brain-penetrant positive allosteric modulator (PAM) of NMDARs. This work highlights the discovery of a related pyridopyrimidinone core with distinct structure-activity relationships, despite the structural similarity to GNE-0723. GNE-5729 (13), a pyridopyrimidinone-based NMDAR PAM, was identified with both an improved pharmacokinetic profile and increased selectivity against AMPARs. We also include X-ray structure analysis and modeling to propose hypotheses for the activity and selectivity differences.

[1]  Benjamin D. Sellers,et al.  Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design. , 2016, Journal of medicinal chemistry.

[2]  Benjamin D. Sellers,et al.  Positive Allosteric Modulators of GluN2A-Containing NMDARs with Distinct Modes of Action and Impacts on Circuit Function , 2016, Neuron.

[3]  Jeffrey M. Blaney,et al.  An integrated suite of modeling tools that empower scientists in structure- and property-based drug design , 2015, Journal of Computer-Aided Molecular Design.

[4]  J. Snyder,et al.  Structural Determinants and Mechanism of Action of a Glun2c- Selective Nmda Receptor Positive Allosteric Modulator Running Title: Analysis of a Glun2c Nmdar Positive Allosteric Modulator , 2022 .

[5]  Qiang Zhou,et al.  NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease , 2013, Nature Reviews Neuroscience.

[6]  M A Rogawski,et al.  AMPA receptors as a molecular target in epilepsy therapy , 2013, Acta neurologica Scandinavica. Supplementum.

[7]  Y. Auberson,et al.  Endoplasmic reticulum stress occurs downstream of GluN2B subunit of N‐methyl‐D‐aspartate receptor in mature hippocampal cultures treated with amyloid‐β oligomers , 2012, Aging cell.

[8]  D. Liotta,et al.  A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors. , 2010, Nature Communications.

[9]  R. Dingledine,et al.  Glutamate Receptor Ion Channels: Structure, Regulation, and Function , 2010, Pharmacological Reviews.

[10]  P. Verhoest,et al.  Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.

[11]  P. Hawkins,et al.  Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.

[12]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[13]  K. Williams,et al.  Developmental switch in the expression of NMDA receptors occurs in vivo and in vitro , 1993, Neuron.

[14]  D. Hackos,et al.  Diverse modes of NMDA receptor positive allosteric modulation: Mechanisms and consequences , 2017, Neuropharmacology.

[15]  K. Nakazawa,et al.  Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes , 2010, Nature Neuroscience.

[16]  A Burger,et al.  Isosterism and bioisosterism in drug design. , 1991, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.